• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    University of Pennsylvania Study Advances Anti-Aging Market

    Pia Rivera
    Feb. 24, 2017 01:18PM PST
    Biotech Investing

    Liberty Biopharma (TSXV:LTY) reported that a study from the Perelman School of Medicine at the University of Pennsylvania found adult stem cells collected from human fat are distinctly more stable than other stem cells. These, in turn, have the potential for use in new therapies for the prevention and treatment of aging-related diseases. As quoted in …

    Liberty Biopharma (TSXV:LTY) reported that a study from the Perelman School of Medicine at the University of Pennsylvania found adult stem cells collected from human fat are distinctly more stable than other stem cells. These, in turn, have the potential for use in new therapies for the prevention and treatment of aging-related diseases.
    As quoted in the press release:

    “The findings of this study are encouraging for the ASC therapies that are being developed by Liberty Biopharma,” stated Dr. Richard Cook, MD, MSc, FRCSC, Chief Medical Officer of Liberty Biopharma. “The University of Pennsylvania researchers’ findings suggest that ASCs may be particularly useful for anti-aging therapies. The study also demonstrated that ASCs are very robust in patients as old as 64 years of age. If the findings from this study are correct, the Liberty Biopharma System for isolating fresh ASCs may be able to support therapeutic options for older patients, whose need for stem-cell therapies is often greater.”

    Click here for the full press release. 

    stem cellsuniversity of pennsylvania
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Hand holding test tube along with longevity-related symbols.

    5 Private Longevity Research Companies

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×